ArticleBlood cancer journal2026

The efficacy, safety, and rationale of orelabrutinib combined with obinutuzumab (O2) as a first-line systemic treatment for marginal zone lymphoma.

Jiadai Xu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.